MUC1 and lung disorder: In 1992, the diagnostic division of Eidia Co., Ltd. (Tokyo, Japan) performed a wide-ranging pioneer study on KL-6 as a serum biomarker of lung diseases and these findings led to the development of an enzyme-linked immunosorbent assay (ELISA) to determine the absolute amount of KL-6 in clinical samples [3].